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Objectifs 
Evaluer l'impact clinique de femmes infectées par de multiples papillomavirus human (HPV) 
à haut risque dont le HPV 16 en comparaison de l'évolution de femmes infectées par du HPV 
16 seul. 
Méthode 
169 femmes ont été classifiées en trois groupes, dépendant de leur profile HPV: HPV-16 seul, 
HPV-16 et un HPV de type bas risque, HPV-16 et un autre HPV à haut risque. Le HPV-DNA 
des frottis cervicaux a été analysé par polymerase chain reaction (PCR) et reverse line blot 
hybridization (RLBH). Toutes les femmes ont été suivies à la consultation de colposcopie 
pour une durée de 24 mois ou plus. La prise en charge s'est faite selon les recommandations 
de Bethesda. 
Résultats 
Les femmes infectées par du HPV 16 et un autre HPV à haut risque n'ont présenté aucun 
changement voire une progression de leur dysplasie en comparaison des femmes des autres 
groupes (RR: 1.39; 95%CI: 1.07 à 1.82; p value: 0.02 à 6 mois; RR: 2.10; 95%CI: 1.46 à 
3.02; p value: <0.001 à 12 mois; RR: 1.82; 95%CI: 1.21 à 2.72; p value: 0.004 à 24 mois). 
Conclusions 
Les femmes présentant une co-infection par du HPV 16 ainsi qu'un autre HPV de haut risque 
voient leur risque d'évolution défavorable augmenter. 
Olivier Cottier, MD; Roland Sahli, PhD; Anca Mihaescu, MD; Pierre De Grandi, MD; 
Michel Boulvain, MD, PhD; Stefan Gerber, PD, MD 
OBJECTIVES: Evaluation of the clinical impact of multiple infec-
tions of the cervix by human papillomavirus, including human pap-
illomavirus-16, compared with single human papillomavirus-16 
infection. 
STUDY DESIGN: One hundred sixty-nine women were classified in 3 
categories depending on their human papillomavirus profile: hu-
man papillomavirus-16 only, human papillomavirus-16 and low-
risk type(s), and human papillomavirus-16 and other high-risk 
type(s). Cervical brush samples were analyzed for human papillo-
mavirus DNA by polymerase chain reaction and reverse line blot 
hybridization. Ali women were evaluated with colposcopy during 24 
months or more. Management was according to the Bethesda 
recommendations. 
RESULTS: Women infected with human papillomavirus-16 and other 
high-risk human papillomavirus type(s) presented more progression 
or no change in the grade of dysplasia, compared with women of the 
other groups (relative risk [RRJ, 1.39; 95% confidence interval [Cil, 
1.07-1.82; P = .02 at 6 months; RR, 2.10; 95% Cl, 1.46-3.02; P < 
.001at12 months; RR, 1.82; 95% Cl, 1.21-2.72; P = .004 at 24 
months). 
CONCLUSION: Coinfection of women with human papil lomavirus-16 
and other high-risk human papillomavirus type(s) increases the risk of 
unfavorable evolution. 
Key words: cervical cancer, cervical dysplasia, human 
papillomavirus infection, human papillomavirus typing 
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ervical cancer is the second most 
frequent cancer in women world-
wide and the principal cancer in most 
developing countries where 80% of the 
cases occur.1'2 Certain types of human 
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papillomaviruses (HPV) are now known 
to be the cause of this disease. HPV in-
fection is a common sexually transmit-
ted disease, which is spontaneously 
cleared in more than 70% of cases within 
1 year.3-5 Women with a persistent infec-
tion have, however, a high risk for cervi-
cal cancer and its precursor lesions ( cer-
vical intraepithelial neoplasia [CIN]) to 
develop.6•7 Screening programs to iden-
tify CIN reduced significantly the mor-
tality and morbidity of this disease.8- 10 
More than 100 HPV types have been 
identified to date, but only a subset is 
found to be associated with malignancy. 
HPV-16 and HPV-18, togethcr with 
HPV-31, -33, -35, -39, -45, -51, -52, -58, 
-59, and others are detected in more than 
95% of all cervical carcinomas. 11 -13 
Other anogenital HPV types are rarely 
associated with malignant tumors and 
have therefore been classified as "low-
risk" (HPV-6, -11, -42, and others) or 
"intermediate-risk" types. 14 Recently, a 
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possible association based on phyloge-
netic trees bas been described between 
HPV-26, -53, and -66 and high-grade 
disease, though not necessarily cervical 
cancer.15,16 
Because women infected with high-
risk HPV types are considered to be at a 
higher risk for the development of cervi-
cal cancer than those who are not in-
fected with HPV or infected with low-
risk HPV types, HPV screening is seen as 
an adjunct to cytologie diagnosis (Papa-
nicolaou [PAP] test smear). 17 Recently, 
it bas been proposed that it may become 
the first step for cervical cancer screen-
ing.18 HPV testing allows also correct 
classification of women presenting with 
borderline PAP smears (atypical squa-
mous cells of undetermined significance 
[ASC-US]).8'9'19 
A relatively large number ofhigh-risk 
HPV s have been shown to persist as 
coinfections on the cervix, raising the 
possibility that oncogenic transforma-
tion and/or persistence may depend on 
the types of viruses that coexist in the 
cervix. Proportions of multiple HPV in-
fections vary from 7% to 44%.20-25 HPV 
coinfection was found less frequently in 
cervical carcinoma than in normal cytol-
ogy and in precancerous lesions,26 con-
sistent with the observation that cervical 
neoplasia is the result of a clonal expan-
sion of a cell infected by a single HPV 
type.7·!1 However, the outcome ofthele-
sion may possibly have a relation with 
the profile ofHPV genotypes.27'28 To test 
this hypothesis, we have compared the 
clinical course of women infected only 
with HPV-16 with that of women in-
fected with HPV-16 and other HPV, ei-
ther high or low risk. 
W e conducted this retrospective cohort 
study from 2000-2003, within the De-
partment of Obstetrics and Gynecology, 
CHUV (University Hospital of Lau-
sanne), Lausanne, Switzerland. This 
study was approved by the institutional 
Ethics Committee. 
Inclusion criteria for women were: the 
identification of an HPV-16 infection on 
an abnormal Pap smear performed in 
liquid-based solution; a delay ofless than 
4 months before the first colposcopy; 
and a previous normal Pap smear within 
a year. A regular follow-up with colpos-
copy had to be documented. The classi-
fication, follow-up, and treatment in our 
colposcopy consultation is in accor-
dance with the Bethesda recommenda-
tions. Exclusion criteria were pregnancy, 
HIV positive, or immunosuppressive 
treatment. 
Cytology and histology were per-
formed at the Institute of Pathology. 
Cervical cells were collected with a cyto-
brush and dispersed in a standard liquid 
solution. All histologie specimens were 
reviewed by an experienced pathologist. 
Three groups were defined: group 1, 
women infected with HPV-16 only; 
group 2, women infected with HPV-16 
and low-risk type(s); and group 3, 
women infected with HPV-16 and other 
high-risk HPV type(s). Undetermined-
risk HPV types were considered as low-
risk types and included in group 2. 
HPV typing was performed systemati-
cally at inclusion and on subsequent ex-
aminations if surgery had been indi-
cated. Typing was performed at the 
Institute of Microbiology as part of its 
routine diagnostic testing using accred-
ited procedures (EN17025). Cells from 
200 µ,L liquid-based solution were col-
lected and DNA was purified using the 
Magna Pure DNA isolation kit (kit no. 
3003990; Roche, Rotkreuz, Switzerland) 
on the Magna LC robot (Roche), and 
eluted in 100 µ,L elution buffer. HPV 
DNA was detected by polymerase chain 
reaction (PCR) and genotyped by re-
verse line blot hybridization (RLBH). 
PCR was performed with 5 µ,L DNA in 
triplicate 50 µ,L reactions using the 
PGMY primers according to Gravitt et 
al,29 with slight modifications. HLA-
DQA primers30 were used as an internai 
standard to assess the quality of the DNA 
and absence of PCR inhibitors. After 
PCR, 5 µ,Lof each reaction was analyzed 
by gel electrophoresis and staining with 
ethidium bromide. Samples were con-
sidered informative if the HLA or the 
HPV DNA fragment could be detected. 
RLBH was performed on positive sam-
ples, essentially as described by Kaufhold 
et al, 31 by using a panel of 31 HPV type-
specific probes (high-risk: 16, 18, 31, 33, 
35,39,45,51,52,56,58,59,68,69,MM4 
[type 82], and MM9 [type 73]; low-risk: 
6, 11, 34, 40,42,44, 53, 54, 57, 70, and 
MM8 [type 84]; undetermined-risk: 26, 
55, 66, and MM7 [type 83]). This proce-
dure has been validated in the course of 
the first World Health Organization in-
ternational collaborative study on detec-
tion of human papillomavirus DNA.:n 
To identify types not represented in the 
panel of probes, sequencing was per-
formed on PCR-positive/hybridization-
negative samples with sequencers from 
Applied Biosystems using the Big Dye 
Terminator chemistry (BDT v.1.1; Ap-
plied Biosystems, Poster City, CA) and 
PGMYl 1 primers. For the purpose of 
this study, those types that did not be-
long to the high-risk group defined pre-
viouslywere classified as lowrisk, de spi te 
recent publications that suggested a 
probable high-risk cytologie progres-
sion, although not oncogenic, associated 
with HPV-26, -53, and-66. 15' 16 
W e recorded the following characteris-
ties of included women: age, number of 
pregnancies, parity, smoking, and use of 
contraceptive methods. 
Ali women were evaluated every 6 
months by cytology and colposcopy, and 
directed tumor-biopsy specimen was 
performed when clinically indicated ac-
cording to cytology results. 
Histology was always performed to re-
solve ASC-US cases into histologie 
grades. When cytologie grades did not 
match the histology, the worse grade was 
used to classify the women. Those grades 
were used to assess evolution of the 
women. 
When a treatment was indicated, laser 
vaporization or loop electrosurgieal ex-
cision procedure (LEEP) was performed. 
Evolution was described by 2 variables 
depending on the histology and/or the cy-
tology. First, referred to as no-improve-
ment, defined as progression or no change in 
the grade of dysplasia during the follow-
up. Second, unfavorable evolution was de-
fined as progression (referred to as progres-
sion) to a higher grade of dysplasia during 
the follow-up. All patients were monitored 
during 24 months or more with colpos-
copy, except those considered as cured. 
Complete recovery to normal state was de-
fined as 3 consecutive normal cytology 
assessments. 
Relative risks (RRs) and 95% confidence 
intervals (Cis) of no improvement and 
unfavorable evolution were calculated, 
comparing group 3 with groups 1 and 2, 
considered together as the reference 
group. Differences between proportions 
were tested using the x2 test. A P value 
Jess than .05 was considered as indicating 
statistieal significance. 
The potential confounding effect of 
treatment was evaluated in a stratified 
analysis (ie, women with and women 
without an intervention during follow-
up). Adjusted RR was calculated using 
the Mantel-Haenszel method. 
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From 2000-2003, 3010 women were fol-
lowed at the colposcopy unit. According 
to exclusion criteria 826 women (27.4%) 
were excluded and 1221 (40.6%) did not 
fit the inclusion criteria, mainly because 
of an abnormal Pap smear in the previ-
ous year or a delay of more than 4 
months before the first colposcopy. Nine 
hundred sixty-three women (32%) cor-
responding to inclusion/exclusion crite-
ria have had an HPV typing. Of these 963 
women, 741 were HPV-16 negative 
(77%) and 222 (23%) were infected with 
HPV-16. Fifty-three women were ex-
cluded because of incomplete follow-up. 
The distribution of the resulting 169 
cases within groups was as follows: 74 
in group 1(44%),27 in group 2 (16%), 
and 68 in group 3 (40%). The median 
age was 27 years (range, 17-70 years), 
71 % had ne ver been pregnan t, 51 % re-
ported having smoked at least 20 ciga-
rettes per day, and 56% reported hav-
ing used oral contraception. There 
were no significant differences in the 
distribution of these factors between 
the 3 groups. 
Among the 74 women in group 1 at in-
clusion ( time 0), 7 (9.5%) were classified 
as ASC-US, 45 (60.8%) as low-grade 
squamous intraepithelial lesion (L-SIL), 
and 22 (29.7%) as high-grade squamous 
intraepithelial lesion (H-SIL) (Table 1). 
For group 2 and group 3 they were, re-
spectively, 1 of 27 (3.7%) and 13 of 68 
(19.1%) ASC-US, 23 of27 (85.2%) and 
46 of 68 (67.7%) L-SIL, and 3 of 27 
(11.1 %) and 9 of 68 (13.2%) H-SIL. The 
evolution of all cases according to initial 
cytology is presented in Table 2. At time 
0, there was no case of cervical cancer. 
Complete regression was observed in 
26% of cases at 6 months of follow-up, 
55.1 % at 12 months, 82.2% at 24 
months, and 95% at more than 24 
months. After more than 24 months of 
follow-up, we observed the persistence 
of dysplasia in 9 women (3 in each 
group ), despite the management. 
Distribution of HPV type and cytology classification at inclusion time 
Variable No. cases ASC-US L-SIL H-SIL 
Group 1 (HPV-16) 7 4 (44%) 7 (9.5%) 45 (60.8%) 22 (29.7%) 
""'''"'"''''''""'"'''"'''' ''''''''''''"'''''''''""''''''''''"'"'''' '"'''"'"'''"'"'''"''''''''''''' 
............................... 
Group 2 (HPV-16 and low risk) 27 (16%) 1 (3.7%) 23 (85.2%) 3 (11.1%) 
''""'''''''"''"'''"'''"'''''''''''''""'''''"'"'"''''''' '''''''''''''''''''''''''''""'''''''''''''''''''''''"" ...................................................................... .. 
Group 3 (HPV-16 and high risk) 68 (40%) 13 (19.1%) 46 (67.7%) 9 (13.2%) 
..................................... ........................................... . ........................................................ . 
'''''''''''"''''''""'"''''''"" 
Total 169 (100%) 21 (12.4 %) 114 (67.5 %) 34 (20.1 %) 
............................ '''''''''''''''''"'''''""'"''''"''''''''''''''' "''''"'''''''""'''''"'''"'''''"'''"""''... . .................................................... .. 
ASC-US, atypical squamous cells of undetermined significance; HPV. human papillomavirus; H-5/L, high-grade squamous 
intraepithelial lesion; L-5/L, low-grade squamous intraepithelial lesion. 
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The percentage of women showing no 
improvement was similar in group 1 and 
group 2 during each time interval (Fig-
ure 1 and Table 3). During the complete 
follow-up of24 months, there was a per-
sisting abnormality in 25.7% and 29.6% 
of women in group 1 and group 2, re-
spectively. The risk of no improvement 
after 6 months was higher in group 3 
compared with group 1 and group 2 (rel-
ative risk [RR], 1.39; 95% confidence in-
terval [CI], 1.07-1.82; P = .02). This ob-
servation was confirmed at 12 months 
(RR, 2.10; 95% CI, 1.46-3.02; P < .001) 
and at 24 months (RR, 1.82; 95% CI, 
1.21-2.72; p = .004). 
We observed a progression of the cer-
vical lesion at 6 months in 16.2% of 
women in group 3, compared with 
10.8% in group 1 and 11.1 % in group 2 
(Figure 2 and Table 4). The risk of pro-
gression at 6 months was higher, but not 
statistically significant, for women in 
group 3, compared with group 1 and 
group 2 (RR, 1.49; 95% CI, 0.68-3.23; P 
= .32). This trend was confirmed at 12 
months: 14.7% ofwomen in group 3 had 
a progression of the lesion, compared 
with 6.8% and 3.7% in group 1 and 
group 2, respectively (RR, 2.48; 95% CI, 
0.94-6.49; P = .06). This became statisti-
cally significant at 24 months (13.2% of 
women in group 3, compared with 4.1 % 
and 3. 7% in group 1 and group 2, respec-
tively) (RR, 3.34; 95% CI, 1.07-10.42; P 
= .03 ). Evolution of cases of group 1 and 
group 2 were not statistically different 
during the complete follow-up with 
about only 4% of progression for both 
groups. 
The interventions reduced the risk of 
no improvement (RR, 0.69; 95% CI, 
0.46-1.04), but this was not statistically 
significant. W e analyzed the effect of 
interventions performed during the 
follow-up on the relative risk of no im-
provement. The relative risk of group 3 
Distribution of cytologie diagnosis during follow-up 
. 
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§ 
c 
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80 
60 
40 
20 
lllASC-US 
DL-SIL 
CIH-SJL 
lacis 0 2 0 0 
................................................... .................................................. .............. . .......................................................................... . 
ASC-US, atypical squamous cells of undetermined significance; GIS, carcinoma in situ; H-5/L, high-grade squamous 
intraepithelial lesion; L-5/L, low-grade squamous intraepithelial lesion. 
Cottier. Risk-gro11p identification for HPV-16 and otiler HPV types. A111] ObstetGyneco/ 2009. 
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Percentage of women 
showing no improvement 
during the follow-up 
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Cottier. Risk-gro11p ide11tificatio11for HPV-l6a11d other 
J-TPV types. Am J Obstet Gy11eco/ 2009. 
compared with group 1 and group 2 
was similar in the subgroup of women 
with an intervention (RR, 2.24; 95% 
CI, 1.19-4.21) and in the subgroup of 
women without intervention (RR, 
1.56; 95% CI, 0.93-2.62). The RR ad-
justed for intervention was 1.68 (95% 
CI, 1.24-2.78). 
ENT 
Our study shows that women infected 
with HPV-16 and another high-risk type 
(group 3) are at higher relative risk of 
unfavorable outcome compared with 
women infected either by HPV-16 only 
(group 1) or by HPV-16 and a low-risk 
type (group 2), consistent with the ob-
servations of Trottier et al.28 HPV types 
of undetermined risk are rarely, if ever, 
detected in cervical cancer11 and were 
thus included in the low-risk group for 
the statistical comparison. Classification 
of undetermined-risk viruses in the low-
risk category (group 2) was justified by 
their neutral statistical effect when they 
were included either in group 2 or in 
group 3 (not shown). Thus, we com-
pared the clinical outcome of the group 3 
women against the group 2 and group 1 
women taken together as control. 
At inclusion time, there was no identi-
fiable group of patients especially at risk 
of cytologie progression when only the 
socioeconomical or risk factor charac-
teristics other than HPV were taken into 
consideration. By definition, all study 
groups were considered high risk be-
cause of inclusion of HPV-16 in each. 
Yet, women infected with HPV-16 and 
another high-risk type (group 3) exhib-
ited a worse clinical outcome compared 
with women infected by HPV-16 only 
(group 1) or by HPV-16 and a low-risk 
type (group 2). The only prognostic dif-
ference of the 3 patient groups was their 
initial profile of HPV infection, because 
they were all subjected to the same clin-
ical management. Thus, group 3 women 
presented a higher risk of no improve-
ment after 24 months and progression 
compared with women of the other 2 
groups. At the present time, most gyne-
cologic practices classify groups of HPV 
infections as high risk vs low risk, with-
out identifying different subgroups. Di-
agnostic tests able to identify multiple 
infections should be used to take advan-
tage of our observation. Such tests are 
now commercially available but need 
further validation and standardization 
for approval in clinical practice. 32 
We were unable to analyze the individ-
ual contribution of each HPV type to the 
Number and percentage of women showing 
no improvement during follow-up 
Start 
Ti me (n = 169) 
Group 1 (HPV-16) 74 
'"'""" 
Group 2 (HPV-16 and low risk) 27 
......................... 
Group 3 (HPV-16 and high risk) 68 
Pvalue 
HPV, human papillomavirus. 
6mo 12 mo 24 mo 
(n = 169) (n = 144) (n = 78) 
36 (48.6%) 22 (29.7%) 19 (25.7%) 
12 (44.4%) 7 (25.9%) 8 (29.6%) 
'"'"""'''''"'"'''''''"''''''''''''''''"'''''''''''''''''''''''''''"'''''''' ............................... .. 
45 (66.2%) 41 (60.3%) 
.02 < .001 
33 (48.5%) 
.004 
Cottier. Risk-grottp ide11tifirntio11 for HPV-l61111d allier HPV types. Am J Obstet Gy11eco/ 2009. 
Percentage of women with 
progression of the cervical 
lesion during follow-up 
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Cottier. Risk-grottp identificatio11 for HPV-16 and allier 
J-TPV types. Am J Obstet Gy11eco/ 2009. 
clinical outcome, as the number of 
women coinfected with each specific 
HPV was too small, and systematic HPV 
typing during the follow-up was not per-
formed. We could not evaluate, in case of 
coinfections, the contribution of each 
type to cervical cancer progression. The 
worst outcome of group 3 compared 
with group 1 could be the consequence 
of a stronger way of high-risk types to 
overcome the natural mucosal defense 
through a synergistic effect mixed infec-
tion. Mixed infections with high-risk 
types may weaken the local immune host 
response, similar to the major immune 
escape described in many tumors, that 
targets the local innate immunity, 
through human a-defensin activity35; 
this local immunity could be overridden 
by mixed infections with high-risk types. 
The host immune cell mediated re-
sponse is essential to reduce and to sup-
press the HPV infection. The interferon 
produced by the T cell and the natural 
killer cells leads to the regression of the 
HPV infection by antiviral, antiprolif-
erative, and immunomodulatory activi-
ties. Although their synergy is not clearly 
established, mixed high-risk types could 
have a stronger negative impact on inter-
feron production by decreasing Thl re-
sponse. 34'35 W e can only speculate that 
mixed infections with high-risk types 
(group 3) increase the chance of a suc-
cessful clonal progression of singly in-
fected cells. It will be necessary to de-
velop a method to assess the immune 
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Number and percentage of women with progression during follow-up 
Ti me 
Group 1 (HPV-16) 
Group 2 (HPV-16 and low risk) 
Group 3 (HPV-16 and high risk) 
Pvalue 
....... 
HPV, human papillomavirus. 
Start 6 mo 12 mo 24 mo 
(n = 169) (n = 169) (n = 144) (n = 78) 
74 8 (10.8%) 5 (6.8%) 3(4.1%) 
................................. , ..................................................................................................................... . 
27 3 (11.1%) 1 (3.7%) 1 (3.7%) 
'''''''""'""'''''''''"'''''''''''''''''''''''''''''''''''""'''''''''''''''''''' ............................ "''''''''''"'""'"''''''''''"'' 
68 11 (16.2%) 10 (14. 7%) 
................................................................... 
.32 .06 
9 (13.2%) 
.03 
Cottier. Risk-group ide11tificatio11 for HPV-16 n11d other H PV types. Am J Obstet Gy11eco/ 2009. 
local mucosal response and to link it with 
HPV type, single or multiple, and cytol-
ogy diagnosis ( ongoing study). It ap-
pears that the immune response of the 
host plays a major role. This point of 
view is also very important in terms of 
vaccination strategies, prophylactic or 
therapeutic vaccine with multivalent 
HPV types, particularly considering the 
combination of HPV-16 and HPV-18, 
the 2 most common high-risk HPV 
types. It is not known whether subjects 
with multiple infections, including sev-
eral cancer-associated HPV, would be 
protected by a vaccine not including all 
cancer-associated types. Interest in coin-
fections has increased in response to the 
possibility of vaccination. The host im-
mune response appears to be mainly 
HPV type specific, but cross-protection 
could offer also a possible benefit, espe-
cially for women infected by multiple 
HPV types. 36•37 For the present, com-
mercial involvement essentially led to 
typization byrisk group ofHPV, and the 
future focuses on a promising multiva-
lent HPV vaccine. 38 
Our study supports the identification 
of a high-risk group of women, infected 
bymultiple high-risk HPV types in addi-
tion to HPV-16. Further studies are 
needed to evaluate the effectiveness and 
cost of a specific follow-up for this 
group. In a therapeutic point of view, a 
prospective study would be needed to 
improve the management of this high-
risk subgroup of women, perhaps with a 
combined approach of local immuno-
modulation and surgery. 
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